NASDAQ: BCDABiocardia Inc Stock
$0.83-0.05 (-5.68%)
Updated Jun 15, 2026
BCDA Price
$0.83
Fair Value Price
$0.30
Market Cap
$9.48M
52 Week Low
$0.78
52 Week High
$2.45
P/E
-0.92x
P/B
-8.89x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.78M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.61
Operating Cash Flow
-$7M
Beta
0.77
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BCDA Overview
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BCDA's potential to beat the market
- BCDA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BCDA
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important BCDA news, forecast changes, insider trades & much more!
BCDA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BCDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BCDA ($0.83) is overvalued by 182.19% relative to our estimate of its Fair Value price of $0.30 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BCDA ($0.83) is not significantly undervalued (182.19%) relative to our estimate of its Fair Value price of $0.30 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BCDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCDA due diligence checks available for Premium users.
Valuation
BCDA fair value
Fair Value of BCDA stock based on Discounted Cash Flow (DCF)
Price
$0.83
Fair Value
$0.30
Overvalued by
181.18%
BCDA ($0.83) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCDA ($0.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BCDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.92x
Industry
16.41x
Market
14.3x
BCDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.89x
Industry
4.89x
BCDA's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.3M
Profit Margin
0%
BCDA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.7M
Liabilities
$2.8M
Debt to equity
-2.61
BCDA's short-term liabilities ($2.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCDA's short-term assets ($1.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BCDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.7M
Investing
-$3.0k
Financing
$117.0k
BCDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BCDA vs Biotech Stocks
Biocardia Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.